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Abstract Hsp90 is an ATP-dependent molecular chap-
erone that regulates key signaling proteins and thereby
impacts cell growth and development. Chaperone cycle of
Hsp90 is regulated by ATP binding and hydrolysis through
its intrinsic ATPase activities, which is in turn modulated
by interaction with its co-chaperones. Hsp90 ATPase
activity varies in different organisms and is known to be
increased in tumor cells. In this study we have quantita-
tively analyzed the impact of increasing Hsp90 ATPase
activity on the activities of its clients through a virtual
prototyping technology, which comprises a dynamic model
of Hsp90 interaction with clients involved in proliferation
pathways. Our studies highlight the importance of
increased ATPase activity of Hsp90 in cancer cells as the
key modulator for increased proliferation and survival. A
tenfold increase in ATPase activity of Hsp90 often seen in
cancer cells increases the levels of active client proteins
such as Akt-1, Raf-1 and Cyclin D1 amongst others to
about 12-, 8- and 186-folds respectively. Additionally we
studied the effect of a competitive inhibitor of Hsp90
activity on the reduction in the client protein levels. Virtual
prototyping experiments corroborate with ﬁndings that the
drug has almost 10- to 100-fold higher afﬁnity as indicated
by a lower IC50 value (30–100 nM) in tumor cells with
higher ATPase activity. The results also indicate a 15- to
25-fold higher efﬁcacy of the inhibitor in reducing client
levels in tumor cells. This analysis provides mechanistic
insights into the links between increased Hsp90 ATPase
activity, tumor phenotype and the hypersensitivity of tumor
Hsp90 to inhibition by ATP analogs.
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Introduction
Hsp90 (Heat shock protein 90) is one of the most abundant
protein of eukaryotic cells, comprising 1–2% of the total
protein under non-stress conditions (Pratt and Toft 2003). It
is mainly an ATP-dependent molecular chaperone which
performs house-keeping functions controlling the activity,
turnover, and trafﬁcking of a variety of proteins (Pratt and
Toft 2003). It plays an important role in the folding of at
least 100 speciﬁc proteins of various signaling pathways
that have crucial role in growth control, cell survival and
development processes and in the refolding of denatured
proteins during proteotoxic stress including heat, oxidative
stress and acidosis (Whitesell and Lindquist 2005).
A unique ATP-binding site, the Bergerat fold, exists in the
N-terminal domain of Hsp90 which is the characteristic
of only some bacterial gyrases, topoisomerases and
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ATP-binding pocket allowed for the development of spe-
ciﬁc Hsp90 inhibitors (Marcu et al. 2000; Garnier et al.
2002;S o ˜ti et al. 2002).
The chaperone function of Hsp90 requires the formation
of a multi-chaperone complex, consisting of Hsp70, Hop,
p23, and Hsp40 and is dependent on ATP-binding and
hydrolysis (Fig. 1; Pratt and Toft 2003; McLaughlin et al.
2002; Siligardi et al. 2004; Panaretou et al. 1998). This
complex binds to key signaling proteins in the metabolic
states and regulates their activities in response to appro-
priate stimuli. It is the inherent ATPase activity of Hsp90
which drives a conformational cycle involving transient
association and dissociation of the N-terminal nucleotide-
binding domains within the Hsp90 dimer (Siligardi et al.
2004). This suggests that binding of ATP to Hsp90 plays an
essential role in the functioning of the Hsp90 chaperone
machinery.
Human Hsp90 in its isolated form has a very weak
ATPase activity (McLaughlin et al. 2002; Richter et al.
2001). The interaction of Hsp90 with its co-chaperones
results in an increase in the inherent ATPase activity for
Hsp90. In fact, the co-chaperones Cdc37, Aha-1, Hop
and p23 modulate Hsp90 ATPase activity signiﬁcantly
(Siligardi et al. 2004; Kamal et al. 2004; Siligardi et al.
2002). An increased ATPase activity correlates with an
increase in the Hsp90 chaperone cycle and increased
processing, folding and release of the active client proteins
(Pratt and Toft 2003).
Hsp90 plays a key role in the conformational maturation
of many signaling proteins and protein kinases like Akt-1
(protein kinase B), Raf-1, Cdk4 (cyclin-dependent kinase
4), which are important regulators of cell proliferation and
survival (Whitesell and Lindquist 2005; Kamal et al. 2004).
All these protein kinases form novel complexes with Hsp90
and are stabilized and activated by the Hsp90 ATP-
dependent chaperone cycle (Sato et al. 2000; Lawlor and
Alessi 2004; Schulte et al. 1995).
In this study, through a dynamic and mathematical in
silico model of Hsp90 interaction with its client proteins
such as Akt and Raf-1 that are involved in cell survival,
proliferation and apoptosis signaling pathways, we quanti-
tatively analyze the effects of modulation of Hsp90 ATPase
activity on cell survival and proliferation endpoints (Fig. 2).
Throughthisvirtual‘what-if’analysis,wegetaninsightinto
the quantitative outcome of increasing ATPase activity of
Hsp90 by different folds and the consequential fold varia-
tions in the activities of its various client proteins. Addi-
tionally, we have performed virtual experiments with an
inhibitor of Hsp90. We analyzed the efﬁcacy of the inhibitor
with increasing ATPase activity and also efﬁcacy of a range
of IC50’s of the inhibitor and its impact on the system with
varying Hsp90 activity. Predictive studies through such
virtual prototyping experiments are insightful in obtaining
Fig. 1 ATP dependent chaperone cycle of Hsp90. The model
describes the chaperone cycle of Hsp90 which depends on ATP
binding and ATP hydrolysis. Partially folded protein is delivered to
Hsp90-ADP via HOP which brings components of Hsp70 and Hsp90
machinery together to form intermediate complex. Hsp70 and HOP
get released from this intermediate complex and ATP substitutes ADP
in Hsp90. Binding of ATP to Hsp90 leads to conformational changes
in N-terminal and middle domains which is required for ATP
hydrolysis and substrate release. After substrate release, Hsp90 is
available for the next round of chaperone cycle (adapted from Pratt
and Toft 2003)
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123mechanistic understanding for known experimental obser-
vations such as increased Hsp90 ATPase activity in tumor
cells (Kamal et al. 2003); getting semi-quantitative infor-
mation on biomarker proﬁles; and also streamlining inhibi-
tor kinetics.
Methods
Model description
The platform consists of the Hsp90 interactome associated
with cell proliferation, survival and apoptosis processes.
The reactions related to binding of Hsp90 with its client
proteins and the stabilization and activation of these clients
in the above cellular processes are detailed. This includes
the ATP-dependent chaperoning cycle of Hsp90 and its
ubiquitous role in the regulation of cellular processes.
Figure 2 is the actual snapshot of the virtual system in
which are highlighted different cellular processes regulated
by Hsp90 that are included in this study. It is a dynamic
model with each reaction represented through an ordinary
differential equation and it predicts the quantitative effects
on the levels of each of the Hsp90 clients, with an increase
in binding afﬁnity for ATP and Hsp90 ATPase activity.
The key sections of the model are qualitatively described in
Supplementary information S1, with the equations and
mechanisms for each node tabulated in Supplementary
information S2.
Model construction
The model is a dynamic representation of Hsp90 ATP-
dependent chaperone cycle and includes kinetic details for
the regulation of Hsp90 client proteins. The time dependent
client protein binding to Hsp90 multi-chaperone complex
and release of the active client following ATP-hydrolysis
has been done utilizing modiﬁed ordinary differential
equations (ODE) and mass action kinetics. The ODEs are
solved by Radau method (Raichur et al. 2006). The Cell-
works proprietary technology, iC-PHYS
TM has been used
to create and simulate the platform.
Model assumptions
The model is a generic Hsp90 centric system and not
speciﬁc to a cell type. The binding afﬁnity of all protein
kinases to Hsp90_cdc37 complex has been assumed to be
Fig. 2 Cellular processes modulated by Hsp90. The ﬁgure illustrates
a high-level view for the cross-talk between the growth factor
receptor pathways and major signaling cascades in tumor cells. It
highlights the presence of both autocrine and paracrine signaling
within the tumor cell, as well as, paracrine inputs from the endothelial
and stromal cell. The growth factor receptors like epidermal growth
factor receptor (EGFR), insulin-growth factor receptor (IGFR) and
hepatocyte growth factor (HGF) activate signaling cascades, resulting
in the activation of key kinases like Akt, IKKa, MAPKS, all of which
converge at the activation of various transcription factors like NFkB,
ETS1 and STATs. As a consequence of these events, downstream
genes like BCL2, Cylcins and MMPs are activated which are
associated with speciﬁc cancer phenotypes of proliferation, apoptosis,
angiogenesis and metastasis. The cross-talk between all of the above
with the basic signaling represents our control oncology platform.
Hsp90 is involved in the stabilization and activation of many of these
client proteins and the increase in ATPase activity has been
represented as a trigger to induce the disease stage
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5,000 lM and ADP at 2,000 lM in the model to maintain a
physiological ratio. The phosphate source has not been
explicitly modeled in the system. It has been assumed that
Hsp90 has a very weak ATPase activity in normal cells,
with a Kf = 1.5E
-1 s
-1 (McLaughlin et al. 2002; Richter
et al. 2001). It has been assumed that ATP-hydrolysis
results in release of active client proteins from Hsp90
chaperone complex. ATP-binding displaces cdc37 from
Hsp90-chaperone complex and only then p23 binds to
Hsp90 in the ATP form. The protein degradation process is
mediated by ubiquitination, but in the system, all degra-
dation processes are shown as irreversible and spontaneous
reactions. A constant source for EGFL6, EGFR, IGF-1R,
PDGFR, PDGF, Her2, Her3 has been assumed in the sys-
tem to account for their constitutive expression due to gain
of function mutations during cancer (Fredrick et al. 2000;
O’Rourke et al. 1997; Puputti et al. 2006; Joensuu et al.
2005).
Simulation protocol
Initial conditions
At initial conditions the model represents normal ATPase
activity for Hsp90 with a Kf of 1.5E
-1 s
-1 (optimized from
the original value of 1.5E
-3 s
-1 mentioned (McLaughlin
et al. 2002; Kamal et al. 2003). The client proteins remain
bound to the Hsp90 chaperone complex and ATP hydro-
lysis drives the release of the active client proteins. Hsp90
and its co-chaperone cdc37 were maintained at a concen-
tration of 10 lM (Carrello et al. 2004) in the system.
Variation in ATPase activity
‘What-if’ analysis or hypothesis testing has been done to
see the effects of increased ATPase activity on the cell
proliferation, survival and apoptosis processes. The ATP-
ase activity of Hsp90 has been hypothetically increased by
10-, 30- and 50-folds. Increased ATP-binding and ATPase
activity of Hsp90 has been shown to occur in tumor cells
(Kamal et al. 2003). The levels of the client proteins
namely Akt-1, Raf-1, Casp9, Bad and Cyclin D1 have been
analyzed with the variation in the ATPase activity.
Inhibitor of Hsp90 ATPase activity
A generic competitive inhibitor has been tested on the
system to observe the effects of reduced Hsp90 ATPase
activity on the processes of cell proliferation, survival and
apoptosis. The kinetics used were for Hsp90 inhibitor
17-AAG (17-(Allylamino)-17-demethoxygeldanamycin)
with a Ki of 4.9E
-2 lM (Kamal et al. 2003). The drug
concentrations used for the study were in the range of 0.1,
0.5, 1, 5 and 10 lM of the drug. It is explicitly assumed that
the concentration of the drug is present at the site of action
post ADME (absorption, distribution, metabolism, and
excretion). Efﬁcacy of the inhibitor with varying Hsp90
ATPase activity has been tested. Additionally, to test the
sensitivity of binding of the inhibitor to systems with
varying Hsp90 ATPase activity, we have tested a wide
range of IC50 values in the range of 30–3,000 nM.
Deﬁnitions of different states
Control state is deﬁned as one in which the ATPase activity
is basal at 0.15 s
-1. A disease state is where the ATPase
activity is 50-fold higher at 7.5 s
-1. The drug was tested in
the disease state at the Ki and concentration mentioned in
‘‘Inhibitor of Hsp90 ATPase activity’’
Results
Effect on activated Akt-1 levels with increase in Hsp90
ATPase activity
Phospho Akt-1, (pAkt-1) a signiﬁcant marker for cell
survival, is a known interactor and a substrate for Hsp90.
Cancer cells that have increased Hsp90 ATPase activity
have been shown to exhibit increased active Akt-1 levels
(Lawlor and Alessi 2004; Kamal et al. 2003).This obser-
vation has been analyzed using a virtual Hsp90 platform
where the ATPase activity of Hsp90 has been increased by
10-, 30- and 50-folds and its effect on the active Akt-1
levels were observed (Supplementary Information S1, Sect.
1.2.1). Active Akt-1 initially shows a stoichiometric
increase in levels with an increasing ATPase activity upto
tenfolds, but beyond a 30-fold rise in ATPase activity the
fold increase in the pAkt-1 levels increases signiﬁcantly
(for a 50-fold increase in the Hsp90 ATPase activity, pAkt-
1 increases by 120-folds; Fig. 3a). This is due to the
existing feed-forward loop from IRS1 present in the system
(Supplimentay Information, Sect. 1.2.2 B). When the feed-
forward loop is switched off, the increase in pAkt-1 levels
remains stoichiometric even with a 50-folds increase in
Hsp90 ATPase activity (Fig. 3b). A comparison between
the two effects has been done in Fig. 3c. As a result of
increased Akt-1 activation with increase in Hsp90 activity,
the downstream targets of Akt-1 in the survival, prolifer-
ation and apoptosis signaling pathways are also increased.
An example of the downstream effects of Akt-1 is the
inactivation due to increased phosphorylation of pro-
apoptotic proteins such as Caspase 9 and BAD, as shown in
Fig. 3d. This shows that with an increase in Hsp90 ATPase
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apoptotic effect.
The effect of increasing ATPase activity on Raf-1P
levels
Raf-1P is another major Hsp90 client and an important
player in the cell proliferation pathway. Raf-1 is stabilized
and activated by Hsp90. Activated Raf-1, further activates
many downstream transcription factors like ELK-1, ATF-2,
NFkB, B-catenin and AP-1, resulting in the expression of
Cyclin D1. Cyclin D1 forms an active complex with the
cell-cycle kinase Cdk4 and helps in the G1-S phase tran-
sition (Kamal et al. 2004; Goetz et al. 2003), acting as a
key biomarker for cell proliferation. With a 50-folds
increase in the Hsp90 ATPase activity, Raf-1P level was
found to be increased by 35-fold. However, a dramatic
increase in the levels of Cyclin D1 (180-folds) is seen even
with a tenfold increase in the ATPase activity, thereby
indicating an increase in cell proliferation. This dramatic
increase in Cyclin D1 levels can be attributed to an
increase in all the transcription factors responsible for its
synthesis. All the above transcription factors are known to
transcribe Cyclin D1 and a reasonable increase in each of
these levels occurs with the increasing Hsp90 ATPase
activity. Figure 4 highlights the effect of increasing ATP-
ase activity on Raf-1P and Cyclin D1 levels, respectively
obtained through virtual prototyping studies.
Fig. 3 Effect of increasing Hsp90 ATPase activity on Akt-1 and its
downstream targets. a Shows increase in active Akt-1 level with feed-
forward loop. b Shows increase in active Akt-1 level without feed-
forward loop. The upper panel in a and b show the graphic
representation of simulation. Simulation program was run for
2 9 10
5 s and the protein concentration was taken when it reaches
saturation. c Comparison between relative change in Akt-1 level with
and without feed-forward loop. d Activated levels of downstream
targets of Akt-1 in the survival pathway also increases with increasing
Hsp90 ATPase activity. The increase in CASP9p and BADp levels
corroborates with that of Akt-1
Fig. 4 Effect of increasing Hsp90 ATPase activity on Raf-1P and
Cyclin D1 levels. Raf-1, a major Hsp90 client protein, is an oncogene
and when over-activated, results in tumor cell proliferation by the AP-
1 mediated expression of Cyclin D1. An increase in Hsp90 ATPase
activity results in an increased level of Raf-1P and Cyclin D1
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of Hsp90 ATPase activity on cell survival
and proliferation endpoints
As indicated by the trends seen an increase in the ATPase
activity of Hsp90 results in an increase in the levels of
active Hsp90 client proteins that are key players in cell
proliferation and survival. We have analyzed how an
inhibitor of Hsp90 ATPase activity would affect these
endpoints (Methods in ‘‘Inhibitor of Hsp90 ATPase
Activity’’). The inhibitor was represented to competitively
inhibit the ATP binding to Hsp90 and thereby interfere
with the normal ATPase cycle of Hsp90 (Goetz et al. 2003;
Banerji et al. 2005; Richter et al. 2001).
Virtual experimental studies reveal that Akt-1 which
increases by 120-folds when ATPase activity is 50-fold
higher than baseline (representative of a cancer condition),
is reduced by almost 24-folds with 1 lM concentration of
the generic inhibitor. Similarly, Raf-1P shows an 18-fold
reduction in levels after having increased to 35-folds in the
high ATPase condition (Fig. 5).
Inhibiting Hsp90 ATPase activity does seem to have a
signiﬁcant impact on the key tumor survival and prolif-
eration markers such as pAkt-1 and Raf-1P, as supported
by successful outcomes of clinical trials of Hsp90 inhib-
itors such as 17-AAG, 17-DMAG, IPI-504, SNX-7081,
Novobiocin (Banerji et al. 2005; Abramson et al. 2008;
Sydor et al. 2006; Rice et al. 2008). Hsp90 has been
widely accepted as a potential cancer therapeutic target
(Goetz et al. 2003; Radanyi et al. 2008; Messaoudi et al.
2008).
Differential sensitivity of the inhibitor with varying
Hsp90 ATPase activity
We analyzed the inhibitor binding afﬁnity and efﬁcacy of
reducing the cell survival endpoints through monitoring
reduction in activated Akt-1 levels. It was observed that
with 1 lM concentration of the inhibitor with Ki of 4.9E
-2,
active Akt-1 levels were reduced by almost 24-folds when
the ATPase activity was 7.5 s
-1 (50-fold) as compared to
only 12-folds with an ATPase activity of 1.5 s
-1 (30-fold;
Fig. 6a). This data clearly indicates that the inhibitor would
be more efﬁcacious when ATPase activity for Hsp90 is
higher, as is seen in cancer cells (Kamal et al. 2003)a s
compared to cells with a lower ATPase activity (normal
cells). Virtual prototyping studies reveal that the inhibitor
will be more effective or sensitive in a cancer condition
marked by a sequential increase in the ATPase activity for
Hsp90 (Fig. 6a).
We also analyzed the drug efﬁcacy by increasing IC50
values for the inhibitor (range between 30 and 3,000 nM)
at a constant drug concentration of 1 lM. A higher IC50
value would essentially mean a lower binding afﬁnity for
the drug and vice versa. It was seen that tumor cells gen-
erally have a lower IC50 value (Kamal et al. 2003). As
shown in Fig. 6b, the drug effectiveness in reducing pAkt-1
levels at 1 lM concentration is decreasing with an increase
in IC50 values. The drug is effective upto an IC50 of
Fig. 5 Effect of Hsp90 ATPase inhibitor in diseased state on Akt1
and Cyclin D1 levels. The above graph shows the fold decrease in the
active Akt-1 and Raf-1P levels in presence 1 lM of the inhibitor
during disease
Fig. 6 Drug efﬁcacy with increase in Hsp90 ATPase activity. a The
above graph shows that the fold decrease in the active Akt-1 levels,
because of the inhibitor, increases with the increasing ATPase activity
for Hsp90. b Differential efﬁcacy of drug on control versus diseased
state with variation in drug IC50. The fold decrease in the active Akt1
levels decreases with increasing IC50 of the drug
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seen. It shows the highest reduction of pAkt-1 by 35-folds
at an IC50 of 30 nM. The impact of this inhibition on a
normal cell with high IC50 value (in the range of lM) will
be less as compared to tumor cell with low IC50 value (in
the range of nM). This analysis indicates that not only the
inhibition of Hsp90 ATPase activity is more effective in
conditions where the system has higher ATPase activity
such as a tumor cell but also it would have higher binding
afﬁnity to this state over a normal state. This study suggests
that inhibition of Hsp90 ATPase activity with a drug
having a low IC50 value less than 100 nM would be ben-
eﬁcial in impacting the key tumor endpoints of prolifera-
tion and survival without much perturbation to the normal
system.
Discussion
Hsp90 is an ATP-dependent molecular chaperone which
performs house-keeping functions controlling the activity,
turnover, and trafﬁcking of a variety of proteins (Pratt
and Toft 2003). It serves as a key convergent node in the
cell signaling circuit not just for the human cell types but
for other organisms as well, based on the concept of
common circuitry and design across varied life forms.
The Hsp90 molecular machinery is dependent on ATP-
binding and hydrolysis and operates as a multi-chaperone
complex. Recent evidence suggests an intricate link
between Hsp90 ATPase activity and structural dynamics
accompanying its chaperoning cycle and the universality
of this across different organisms (Southworth and Agard
2008).
There has been experimental evidence of different states
of a system (i.e., normal vs. tumor states) having varying
Hsp90 ATPase activity (Kamal et al. 2003). Furthermore,
the Hsp90 activity characterized from different organisms
exhibit widely different ATPase activities (Owen et al.
2002). While the reason underlying varying ATPase
activities of Hsp90 from different systems remain
unknown, this study makes an effort to quantitatively study
the consequence of this variation in its catalytic efﬁciency
on maturation of its client proteins and its overall impact
on organism growth. Virtual analysis shown here has also
revealed that variation in catalytic activities of Hsp90 from
different systems may confer differential sensitivities to
small molecule inhibitors of Hsp90. This dynamic, com-
putational, quantitative analysis of Hsp90 networks shown
here provides a theoretical framework to analyze the
impact of varying its ATPase activity on maturation of its
clients, progression through signaling pathways and
organism growth. In addition, it provides a basis to predict
the extent of growth inhibition conferred by generic Hsp90
inhibitors on organisms with differing Hsp90 ATPase
acitivities.
Hsp90 is a molecular target for cancer therapeutics and
Hsp90 inhibitors are now widely being tested in clinical
trials for depletion of clients including several oncogenic
kinases (Kamal et al. 2004; Goetz et al. 2003; Issacs et al.
2002; Stepanova et al. 1996; Smith et al. 2008). More than
being just a cancer therapeutic target, Hsp90 inhibitors are
now extensively being tested for treatment of other dis-
eases including neurodegenerative disorders (Waza et al.
2005; Dickey et al. 2007), rheumatoid arthritis (Rice et al.
2008), diabetes (Yang et al. 2009), malaria as well as other
infectious diseases of fungal and viral origin (Banumathy
et al. 2003; Wider et al. 2009; Nicola et al. 2008; Chase
et al. 2008). The regulation of various client proteins by
Hsp90 highlights its ubiquitous role in various organisms
like Plasmodium falciparum (Banumathy et al. 2003;
Acharya et al. 2007), Candida albicans (Solit and Chiosis,
2008), Aspergillus fumigates, Cryptococcus neoformans
(Cardenas et al. 1999) and Vaccinia virus (Hu and Seeger
1996).
In light of the key role of Hsp90 in many organisms and
disease processes, we analyzed the effect of a generic
Hsp90 competitive inhibitor on the system and could
substantially conclude from the results that the sensitivity
(binding afﬁnity) towards inhibition would increase with
the increasing ATPase activity for Hsp90. For instance, a
tenfold increase in ATPase activity has shown 12%
increase (Fig. 6a) in inhibition by an Hsp90 inhibitor like
geldanamycin. The analysis has also shown that inhibition
of ATPase activity of Hsp90 is efﬁcacious in reducing the
cell survival and proliferation endpoints.
The results support the notion that an increased ATPase
activity for Hsp90 during cancer (Kamal et al. 2003) would
also increase its sensitivity to a particular inhibitor targeting
inhibition of its ATPase activity. Hence, a speciﬁc Hsp90
inhibitor would be more effective against a cancer cell with
higher ATPase activity in preference to a normal cell. Our
studies indicate that an inhibitor to Hsp90 such as 17-AAG,
17-dimethylaminoethylamino-17-demethoxy-geldanamycin
(17-DMAG)wouldbe15-to25-foldmoreeffectiveagainsta
cancer cell with a higher ATPase activity as compared to the
normal cell with a very weak ATPase activity for Hsp90.
Reducing survival and proliferation speciﬁcally of the tumor
cellsistheneedofanhourinordertoovercomethetoxicside
effects of chemotherapeutic drugs.
Hsp90 inhibitors presently under clinical trials include
17-AAG (NC1, Kosan Biosciences), KOS-953 (Kosan
Biosciences), CNF-1010 and CNF-2024 (Biogen Idec),
IPI-504 (Inﬁnity Pharmaceuticals)and SNX-5422(Serenex;
Solit and Chiosis 2008). Most of these are now under Phase
II and Phase III clinical trials. These inhibitors induce
depletion of the clients by blocking the binding of ATP to
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Other inhibitors that target co-chaperone proteins like
Cdc37 (Smith et al. 2008) and Hop (Yi and Regan 2008) are
also being studied as an alternative approach to inhibit
Hsp90 mediated activation of various client proteins.
This dynamic virtual system can also be used to study
the role of Hsp90 activity on other phenotypes that are
affected in cancer such as increased angiogenesis, metas-
tasis, and increased expression of drug resistance proteins.
Through this study we present a novel approach for target
validation and understanding the efﬁcacy of manipulating a
target in normal versus abnormal cell systems. The study
strongly supports the role of Hsp90 as a ‘‘Master switch’’
for cell survival and proliferation and a therapeutic target
(Goetz et al. 2003; Banerji et al. 2005; Beliakoff and
Whitesell 2004).
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